Alternative statutory remedy and unexplained delay barred writ review of customs confiscation adjudication, leaving merits for appellate consideration...
Authorised courier due diligence protects against penalties where declared exports conceal prohibited goods despite proper documentation and customs p...
Customs-controlled container movement now extends to DP World facilities, subject to segregation, inspections, reconciliation, and EXIM cargo priority...
Under Customs Act s.25(1), MoF amended notification 16/2017-Customs to expand customs duty exemptions for specified pharmaceutical drugs distributed through Patient Assistance Programs (PAPs). The amendment adds 37 new pharmaceutical products (entries 53-89) from multiple manufacturers including MSD Pharmaceuticals, Pfizer, Novartis, AstraZeneca, Johnson & Johnson, Merck, Takeda, GSK, and Roche. The exempted drugs include treatments for cancer, rare diseases, and autoimmune conditions. The notification takes effect from February 2, 2025, demonstrating government's commitment to improve access to specialized medications through manufacturer-sponsored patient support programs.
Under Customs Act s.25(1), MoF amended notification 16/2017-Customs to expand customs duty exemptions for specified pharmaceutical drugs distributed through Patient Assistance Programs (PAPs). The amendment adds 37 new pharmaceutical products (entries 53-89) from multiple manufacturers including MSD Pharmaceuticals, Pfizer, Novartis, AstraZeneca, Johnson & Johnson, Merck, Takeda, GSK, and Roche. The exempted drugs include treatments for cancer, rare diseases, and autoimmune conditions. The notification takes effect from February 2, 2025, demonstrating government's commitment to improve access to specialized medications through manufacturer-sponsored patient support programs.
Note: It is a system-generated summary and is for quick reference only.
TaxTMI 
TaxTMI 
of 4828 
Join Channel 
